A Putative Nononcogene Addiction Gene Target and Marker for Radiosensitivity in High-Risk Prostate Cancer
Final rept. 30 Sep 2011-29 Sep 2014
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
We proposed that RNASEH2A represents a novel type of gene, up-regulated in lethal prostate cancer to prevent catastrophic genomic instability and cell death and thereby acting to make prostate cancers resistant to treatment with radiation therapy. The major findings include 1 Expression of RNASEH2A in human prostate cancer cell lines. 2 Ability to modulate RNASEH2A expression genetically 3 Modulation of cell cycle, cell migration, transcription invasion and growth of prostate cancer cell lines with RNASEH2A. 4 Radio-resistance of prostate cancer cells that over express RNASEH2A. 5 Association of RNASEH2A with tumor grade. 6Observation that RNASH2A expression does not independently predict lethal prostate cancer.7Observation that RNASH2A expression does predict radio-sensitivity and response to treatment in men who underwent radical prostatectomy and subsequently had post operative radiation.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research